Kaken Pharmaceutical Co., Ltd. (4521.T) JPX

Currency In JPY

Key Executives

Name	Title	Pay	Year Born
Hiroyuki Horiuchi	Chairman, President & Representative Director	103M	1962
Masashi Suzudo	MD, Director of the Corporate Planning & Coordination Department and Director	0	1962
Keizo Kimura	Corporate Officer, Chief Officer of Production Division & Chief of Shizuoka Factory	0	N/A
Tomohiro Takaya	General Manager of Legal Affairs & Intellectual Property Department	0	N/A
Gaku Kametsu	General Manager of Corporate Communications Department	0	N/A
Mitsuru Watanuki	Chief Officer of R&D Division and Director	0	1964
Tomoyuki Koseki	Chief Officer of Marketing & Sales Division	0	N/A
Masaru Ogawa	Chief Officer of Regulatory Affairs Division & GM of Regulatory Affairs Department	0	N/A
Hideki Kawabata	Head of Clinical Development Department	0	N/A
Tatsuhiro Harada	Deputy Chief Officer of R&D Division & Chief of Drug Research Center	0	N/A

Name

Title

Pay

Year Born

Hiroyuki Horiuchi

Chairman, President & Representative Director

103M

1962

Masashi Suzudo

MD, Director of the Corporate Planning & Coordination Department and Director

1962

Keizo Kimura

Corporate Officer, Chief Officer of Production Division & Chief of Shizuoka Factory

N/A

Tomohiro Takaya

General Manager of Legal Affairs & Intellectual Property Department

N/A

Gaku Kametsu

General Manager of Corporate Communications Department

N/A

Mitsuru Watanuki

Chief Officer of R&D Division and Director

1964

Tomoyuki Koseki

Chief Officer of Marketing & Sales Division

N/A

Masaru Ogawa

Chief Officer of Regulatory Affairs Division & GM of Regulatory Affairs Department

N/A

Hideki Kawabata

Head of Clinical Development Department

N/A

Tatsuhiro Harada

Deputy Chief Officer of R&D Division & Chief of Drug Research Center

N/A

Description

Kaken Pharmaceutical Co., Ltd. is involved in the development, manufacturing, and commercialization of a diverse range of medical goods, health devices, and agricultural chemicals, serving both domestic and global markets. Their extensive product portfolio includes specialized treatments like Clenafin, a topical solution for fungal nail infections; Artz, an agent combating osteoarthritis; Seprafilm, an absorbable film preventing surgical adhesions; Fiblast, a spray designed for pressure and skin ulcer healing; Regroth for periodontal tissue regeneration; and Hernicore, which addresses lumbar disc herniation. They also market Adofeed, a plaster for pain and inflammation relief; Ebrantil for dysuria and hypertension management; Procylin, an oral prostaglandin I2 analogue; Lipidil, used to treat high cholesterol; Mentax, an anti-fungal cream; and Loxoprofen Na Tape, another pain-relieving and anti-inflammatory patch. Additionally, Ropion is offered as an injectable pain medication. The company's agricultural and animal health division provides products such as Polyoxins, a fungicidal agent; Pentoxazone, a herbicide for rice crops; and Salinomycin, an anti-coccidial feed additive for poultry. Kaken Pharmaceutical is actively advancing several investigational compounds. BBI-4000 has completed its Phase III clinical trials for primary axillary hyperhidrosis, while KMW-1 is also in Phase III for managing eschar removal in thermal burns. KAR is being developed for hide lice infestation, and KP-607 is currently in Phase II for the treatment of onychomycosis. Beyond pharmaceuticals, the firm also manages the rental of the commercial property, Bunkyo Green Court. Its products are sold under various brand names, including Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia. The company holds licensing agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Established in 1917, Kaken Pharmaceutical Co., Ltd. has its main office situated in Tokyo, Japan.